Drug Trial Radar · NCT07207070
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
312
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
May 31, 2029
Study completion May 31, 2030
Sponsor
- Lead sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
JS105Drug
Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.
DalpiciclibDrug
Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle;
Fulvestrant 50 Mg/mL Intramuscular SolutionDrug
Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blind Independent Central Review (BICR) assessed PFS based on RECIST v1.1 (BICR-PFS)Time frame: Up to 3.5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chinese Acadamy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Henan Provincial Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.